FIELD: medicine; pharmaceuticals.
SUBSTANCE: group inventions relates to local pharmaceutical compositions for treating hyperproliferative skin disease, Gorlin syndrome, basal cell carcinoma, sebaceous hyperplasia or psoriasis comprising N-[6-((2R,6S)-2,6-dimethylmorpholino)pyridin-3-yl]-2-methyl-4'-trifluoromethoxy)biphenyl-3-carboxamide, a solvent mixture consisting of dimethylisosorbide, propylene glycol, diisopropyl adipate and benzyl alcohol, an oil phase, antioxidants, texture enhancers, surfactants and preservatives. In addition, group of inventions relates to a method of treating a hyperproliferative skin disease, Gorlin syndrome, basal cell carcinoma, sebaceous hyperplasia or psoriasis using disclosed compositions.
EFFECT: group of inventions provides compositions that effectively deliver active agent into skin, limiting systemic exposure, skin permeability is maintained at acceptable levels, favorable from standpoint of patient tolerance and stable.
5 cl, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| BIOMARKERS FOR THERAPY, BASED ON HEDGEHOG INHIBITOR | 2012 |
|
RU2602185C2 |
| USING SMOOTHENED ANTAGONISTS FOR TREATING HEDGEHOG PATHWAY RELATED DISORDERS | 2009 |
|
RU2519200C2 |
| COMPOUNDS AND COMPOSITIONS AS MODULATORS OF HEDGEHOG PATHWAY | 2007 |
|
RU2413718C2 |
| PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PSORIASIS | 2020 |
|
RU2742879C1 |
| SIGMA-LIGANDS FOR APPLICATION IN PREVENTION AND/OR TREATMENT OF POSTOPERATIVE PAIN | 2011 |
|
RU2569055C2 |
| COMPOSITIONS AND METHODS OF TREATING PARANASAL SINUS AND PARASITIC NASAL MUCOSA DISEASES WITH NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | 2017 |
|
RU2718061C1 |
| PHARMACEUTICAL COMPOSITIONS, CONTAINING IMATINIB AND RELEASE MODERATOR | 2006 |
|
RU2404775C2 |
| TREATMENT OF CHRONIC HAND SKIN ECZEMA | 1998 |
|
RU2238083C2 |
| SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR MODULATORS AND USING THEM FOR TREATING MUSCULAR TISSUE INFLAMMATION | 2009 |
|
RU2521286C2 |
| 11β-HYDROXYSTEROID DIHYDROGENASE INHIBITORS | 2008 |
|
RU2440989C2 |
